{"entity":{"id":"gcig-ca125","kind":"term","name":"GCIG CA-125 response and progression criteria (ovarian cancer)","aka":["GCIG criteria","GCIG CA-125 criteria","CA-125 progression","CA-125 response","Rustin criteria"],"tldr":"The GCIG criteria define when a fall in the CA-125 blood test counts as a response, and when a rise counts as progression, for ovarian cancer.","summary":"The Gynecological Cancer Intergroup had agreed criteria for defining progression-free survival after first-line treatment and response in recurrent disease using CA-125. Rustin and colleagues (International Journal of Gynecological Cancer 2011) wrote detailed definitions that incorporate RECIST 1.1, for use in trial protocols; by then the progression criteria had been validated for recurrent disease. They were developed in patients on chemotherapy and had not been validated with targeted drugs.","asOf":"2026-11-04","links":[{"label":"Rustin et al., Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the GCIG (Int J Gynecol Cancer 2011)","url":"https://doi.org/10.1097/igc.0b013e3182070f17"}],"tags":[],"related":["ca-125","recist","o-rads"],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Endpoints"},"route":"/terms/gcig-ca125/","neighbours":{"term":[{"id":"ca-125","kind":"term","name":"CA-125","route":"/terms/ca-125/"},{"id":"o-rads","kind":"term","name":"O-RADS (Ovarian-Adnexal Reporting and Data System)","route":"/terms/o-rads/"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/"}],"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}]}}